Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
View MissionIR's Instablogs on:
  • Koss Corp. (KOSS) Enters Partnership With Mossy Oak┬« To Create Three New Headphone Products

    Koss, a high fidelity stereophone manufacturer and inventor of the world's first SP/3 Stereophone in 1958, based in Milwaukee, Wisconsin, announced a partnership with Mossy Oak.

    The partnership will allow for the combination of Mossy Oak's award winning patterns and Koss Corporation's headphones. Specifically, the Break-Up Infinity® and Break-Up® patterns will be applied hydrographically to three unique styles of headphones: a full-size stereophone, an on-ear stereophone, and two sets of earbud stereophones.

    The Koss KMO20G full size stereophone has been designed specifically to maximize comfort, durability, and performance. Extended frequency response was achieved through the implementation of dynamic elements throughout the stereophone, and large leatherette ear cushions were used to deliver maximum isolation. A tough exterior and additional headband sling make the KMO20g headphones reliable and comfortable.

    The Koss KMO15 on-ear stereophone is a lightweight headphone perfect for the outdoor lifestyle. In-line volume control allows for quick and easy volume adjustment without the hassle of fiddling around with the MP3 player.

    Ideal for the outdoor user, the KMO5 earbud fuses durability, portability, and the Sound of Koss into one reliable package. The Koss KMO10 earbud includes two earbuds so you never have to go without the Sound of Koss.

    "We are excited to have the Mossy Oak line of stereophones hit the market," Michael J. Koss, President and CEO said today. "Both companies have very loyal customers who appreciate and expect quality products. We are thrilled to reach new customers and provide our existing customers with such an exclusive product."

    For more information, please visit www.koss.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Tags: KOSS
    Jul 11 2:07 PM | Link | Comment!
  • VolitionRX Ltd. (VNRX) Strives To Bring Groundbreaking Simple Cancer Detection Blood Tests To Market

    VolitionRX is a life sciences company endeavoring to bring to market a range of epigenetic cancer detection blood tests that are as common and easy to use as diabetic and cholesterol tests currently available on similar formats. The company is managed by a seasoned team that is well-respected and experienced in diagnostics and commercialization.

    Volition's focus is meeting the urgent and unmet need for large-scale and low cost early detection tests in the cancer diagnostic market. Chances for cancer survival are greatly improved by early detection and diagnosis, which makes VolitionRX's efforts potentially invaluable.

    Volition is in the process of developing a range of blood-based epigenetic cancer early detection tests that are planned to be released for research and then clinical use in Europe, North America, and across the globe. The tests, once developed, will be marketed under the NuQ brand name and will include: NuQ, a general blood test for detecting the level of all nucleosomes in a patient's blood; NuQ-X, a family of blood tests that detect nucleosomes containing specific nucleotides; NuQ-V, a family of tests that detect nucleosomes containing specific histone variants that identify the type of cancer present; and NuQ-M, a family of tests that detect nucleosomes containing modified histones that can be used as a blood test for individual cancer types.

    These tests are being developed to work together. The basic NuQ test will serve as a frontline test for the level of nucleosomes in the blood. If this test's results are negative, it means there is likely no cancer present and further testing is not immediately needed. If the results of the test are positive, however, the patient may possibly have cancer or another condition, requiring further testing to confirm this and, if cancer exists, to determine the specific subtype of cancer. This determination will be made using the NuQ-V tests and the NuQ-M test, collectively called the NuQ panel.

    The Nucleosomics tests are protected by worldwide patent applications and the U.S. Research institutions will soon be able to purchase the NuQ test. It is Volition's intention that the tests will be available to clinical patients thereafter under the NuQ brand. The company's planned range of simple blood tests will continue to expand on increasingly simple formats with both general and specific cancer tests.

    Volition is additionally in the process of developing a technology called HyperGenomics, aimed at determining specific epigenetic signatures from cancer biopsies by reading "hypersensitive sites" along the DNA string. Being developed as a second-line once cancer has been diagnosed, these tests will accurately determine the specific subtype of disease and help decide the most appropriate therapy.

    Established in 2010, VolitionRX currently houses its primary development activities in Belgium, augmented by commercialization work in Singapore. The focus of this commercialization work is to bring the company's pioneering diagnostic products to market, first in Europe, then the United States, and then around the world.

    For more information, visit the company's Web site at www.volitionrx.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Jul 11 2:06 PM | Link | Comment!
  • Duma Energy Corp. (DUMA) To Expand Beyond U.S. Borders With African Concession

    Duma Energy just announced that it has entered into the final stage of negotiations to acquire a private corporation with a significant interest in an African concession totaling approximately 6 million acres (25,000 square km). This acquisition would be part of the company's intention to expand internationally and acquire highly prospective opportunities in emerging exploration regions.

    "Our success in the last two years has put us in a strong position for growth. We believe it is the right time to be aggressive and continue to pursue our stated goal of seeking projects that offer huge potential returns. There are great opportunities out there," stated Jeremy G. Driver, President and Chief Executive Officer of Duma Energy Corp.

    Duma Energy is actively producing oil and gas in the continental United States, both on and offshore. Leveraging its technical expertise, promising portfolio, and strong financial condition, the company plans to utilize domestic revenues and cash flow to fund its rapid growth through acquisition, while participating in transformational projects with the potential of providing exponential returns for shareholders.

    For additional information, visit the company's website at www.DUMA.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Jul 11 2:05 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.